| Similar Articles |
|---|
 |
The Motley Fool
December 1, 2010
Brian Orelli |
We're Still Buying. Probably. Despite manufacturing problems, Johnson &Johnson continues with its purchase of Crucell.   |
The Motley Fool
March 24, 2011
Anand Chokkavelu |
Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund." |
The Motley Fool
July 2, 2009
Brian Orelli |
Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company. |
The Motley Fool
October 17, 2006
Brian Lawler |
See Johnson & Johnson Crawl Earnings growth isn't moving right along because the company has become so big. Investors, take note. |
The Motley Fool
August 19, 2010
Brian Orelli |
Buffett Is Buying J&J. Should You? It depends on your time horizon. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years. |
The Motley Fool
August 15, 2007
Brian Orelli |
Buffett's Drug Deals During the most recent quarter Berkshire Hathaway has increased their holdings in several battered pharmaceutical and medical stocks. |
The Motley Fool
September 4, 2009
Brian Orelli |
The Billion-Dollar Lovers' Quarrel Continues Elan had better bring candy and flowers to patch this up. |
The Motley Fool
September 24, 2010
Anand Chokkavelu |
10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list |
The Motley Fool
September 15, 2009
Brian Orelli |
What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri. |
The Motley Fool
February 24, 2009
Brian Orelli |
Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success. |
The Motley Fool
August 17, 2010
April Taylor |
Buffett Buys: A New Stock and Doubling Down on J&J Berkshire Hathaway's Warren Buffett was back in buying mode during the second quarter; the big moves were the addition to Berkshire's stake in Johnson & Johnson and establishment of a new position in Fiserv. |
The Motley Fool
September 25, 2009
Brian Orelli |
Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK. |
The Motley Fool
September 14, 2009
Brian Orelli |
The Clock Is Ticking for Elan Elan is getting closer to the Sept. 26 deadline to fix its contract with Johnson & Johnson. If it doesn't, Biogen Idec has the right to take full control of Elan's and Biogen's multiple-sclerosis drug, Tysabri. |
The Motley Fool
August 7, 2009
Brian Orelli |
A Billion-Dollar Lovers' Quarrel It looks like the triangle between partners Elan and Biogen Idec and third-wheel Johnson & Johnson over the multiple sclerosis drug Tysabri is going to get settled in court. |
The Motley Fool
February 22, 2010
Brian Orelli |
So Long, See You in Arbitration After another rejection, Johnson & Johnson and Basilea call it quits. |
The Motley Fool
May 26, 2010
Brian Orelli |
Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues. |
The Motley Fool
April 8, 2008
Brian Lawler |
Novartis Sees More Growth Ahead Novartis makes one of the largest acquisitions in health-care history. |
The Motley Fool
December 1, 2008
Brian Orelli |
Johnson & Johnson Firms Things Up The health-care giant acquires breast-implant maker Mentor. |
The Motley Fool
October 7, 2010
Anand Chokkavelu |
How Johnson & Johnson Really Makes Money Hint: It's not Tylenol. |
The Motley Fool
October 27, 2009
Brian Orelli |
Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions? |
The Motley Fool
August 18, 2009
Morgan Housel |
Warren Buffett Goes Buying ... and Selling Warren Buffett's moves over the years would leave you well ahead of the pack. Here's a rundown of Berkshire's latest buys and sells. |
The Motley Fool
December 4, 2008
Brian Orelli |
Drug Deals Require Cash Pharmaceutical companies have been hoarding cash -- patiently waiting for good prices. And it looks like that time has arrived. Take a look at some players in the pharmaceutical field. |
The Motley Fool
July 20, 2010
Brian Orelli |
Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant. |
The Motley Fool
January 15, 2010
Brian Orelli |
The Odor Lingers at Johnson & Johnson The company has to recall products because of a smelly problem. |
The Motley Fool
August 24, 2010
Brian Orelli |
One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well. |
The Motley Fool
September 27, 2010
Brian Orelli |
This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time. |
The Motley Fool
October 19, 2011
Brian Orelli |
Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson. |
The Motley Fool
October 12, 2007
Billy Fisher |
Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
January 28, 2011
Anand Chokkavelu |
10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo. |
The Motley Fool
October 14, 2008
Brian Orelli |
Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace. |
The Motley Fool
December 31, 2009
Brian Orelli |
The FDA (Still) Hates Antibiotic Makers Johnson & Johnson and Basilea are the agency's latest victims. |
The Motley Fool
October 12, 2004
Alyce Lomax |
Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson? |
The Motley Fool
November 26, 2007
Brian Orelli |
Johnson & Johnson Reorganizes -- Who Wins? Johnson & Johnson announces the second phase of its reorganization plan. While it may take years to see whether the measures will help J&J, some other companies could benefit far more quickly. |
The Motley Fool
August 27, 2009
Brian Orelli |
Elan and J&J, Sitting in a Tree ... Johnson & Johnson dumps Alkermes for its new best bud in favor of Elan |
The Motley Fool
May 20, 2011
Andrea Kalvesmaki |
Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings. |
The Motley Fool
May 4, 2010
Brian Orelli |
Earnings Growth Trumps Revenue Growth, Except Here A solid quarter for Pfizer, but is there more in the tank? |
The Motley Fool
March 23, 2009
Brian Orelli |
Which Pharmas Still Have Cash? Pharmaceutical mergers-and-acquisitions activity has been jumping for the past few months, but the consolidation can't go on forever. |
The Motley Fool
February 11, 2010
Brian Orelli |
Blockbuster in Hand, It's Time to Show a Profit Elan predicts an operating profit for the first time in nine years. |
BusinessWeek
September 30, 2009
Arlene Weintraub |
J&J Tries to Buy Itself a Pipeline It's snapping up biotechs, spearheading innovative alliances, and reshuffling R&D. |
The Motley Fool
September 30, 2009
Brian Orelli |
More Questions Than Answers From Elan Things that make you go hmmm. |
The Motley Fool
November 13, 2007
Brian Orelli |
Another Punch in the Nose for Pfizer The FDA clears ZYRTEC-D for over-the-counter sales; marketing of the medication will now switch hands from Pfizer to Johnson & Johnson. Investors, take note. |
The Motley Fool
May 18, 2009
Morgan Housel |
Warren Buffett Goes Shopping Berkshire's latest quarterly filing shows substantial purchases in two of his favorite banks: Wells Fargo and US Bancorp, consumer products maker Johnson & Johnson, and a sale of ConocoPhillips. |
The Motley Fool
November 26, 2010
Brian Orelli |
Get It Together, Johnson & Johnson Another day, another recall. |
The Motley Fool
October 12, 2007
Billy Fisher |
Dueling Fools: Johnson & Johnson Bear The bearish opinion on J&J is that it is an impressive company that may have its best days behind it. |
The Motley Fool
June 4, 2010
Brian Orelli |
Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other. |
The Motley Fool
October 7, 2010
Anders Bylund |
Affymax Shares Plunged: What You Need to Know Affymax plunged as much as 11.6% in early trading today after an unfavorable ruling in a patent dispute with larger drug developer Johnson & Johnson. |
The Motley Fool
May 12, 2009
Brian Orelli |
Another Reason to Hate Big Pharma's M&A As we get closer to Pfizer and Merck wrapping up their deals, it looks like a new group is voicing their displeasure: external partners. |
The Motley Fool
August 4, 2010
Mac Greer |
One Biotech Stock Ready to Rebound? One of our analysts gives you his thoughts on Elan. |
